GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE89891 Query DataSets for GSE89891
Status Public on Dec 20, 2017
Title Inhibition of the H3K9 methyltransferase epigenetic regulator G9A attenuates oncogenicity but provokes a survival response via activation of the hypoxia pathway
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Epigenetic mechanisms play important roles in the regulation of tumorigenesis, and hypoxia-induced epigenetic changes may be key drivers of the adaptation of cancer cells to the hypoxic microenvironment typical of solid tumors. Previously, we showed that loss-of-function or inhibition of the oncogenic H3K9 methyltransferase G9A attenuates tumor growth and constitutes an important strategy for cancer management. However, the mechanisms by which blockade of G9A leads to a tumor suppressive effect remain poorly understood. Here, we show that G9A is highly expressed in breast cancer compared to normal breast tissue and is associated with poor prognosis in patients, where it may function as a potent oncogenic driver in this cancer type. In agreement with this, G9A inhibition leads to increased cell death, impaired cell migration, reduced cell cycle and downregulated anchorage-independent growth. Interestingly, whole transcriptome analysis revealed that a number of previously non-responsive genes become amenable to hypoxia following G9A inhibition, including many targets that drive cancer cell survival. This was accompanied by the upregulation of the hypoxia inducible factors HIF1A and HIF2A during the use of G9A inhibition to curb cancer cell growth even under normoxic conditions. Therefore, we show that G9A is a key mediator of oncogenic processes in breast cancer cells and cancer therapeutics involving G9A inhibition can be used successfully to attenuate oncogenicity. However, cancer cells mount a survival response via activation of the HIF pathway that may necessitate the additional suppression of HIF signaling for improved efficacy in the eradication of the disease.
Overall design 27 samples consisting of MCF7 human breast cancer cells treated with 6 μM BIX-01294 in 0.1% dimethyl sulfoxide (DMSO) or 0.1% DMSO carrier controls and untreated controls in acute (4 hours) hypoxia, chronic (24 hours) hypoxia (1% O2) or normoxia (21% O2) control conditions in triplicate cultures.
Contributor(s) Ho JC, Ueda J, Pang QY, Kato H, Jha S, Yang H, Poellinger L, Lee KL
Citation(s) 29145444
Submission date Nov 15, 2016
Last update date Jun 13, 2019
Contact name Kian Leong LEE
Phone +(65) 6601 3685
Organization name National University of Singapore (NUS)
Department Duke-NUS Medical School
Lab Cancer & Stem Cell Biology Program (CSCB)
Street address #07-21, 8 College Road
City Singapore
State/province Singapore
ZIP/Postal code 169857
Country Singapore
Platforms (1)
GPL10558 Illumina HumanHT-12 V4.0 expression beadchip
Samples (27)
GSM2392640 MCF7 Normoxia No Treatment, Replicate 1
GSM2392641 MCF7 Normoxia No Treatment, Replicate 2
GSM2392642 MCF7 Normoxia No Treatment, Replicate 4
BioProject PRJNA353654

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE89891_RAW.tar 26.2 Mb (http)(custom) TAR
GSE89891_non-normalized.txt.gz 7.9 Mb (ftp)(http) TXT
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap